NanoViricides is trading 8.52% higher at $1.66 in pre-market, rebounding from its September 22 close of $1.53; no immediate catalyst has been identified. - No fresh company announcement or clearly identified overnight catalyst was found for September 23. - The latest substantive update is the planned Phase II NV-387 Ebola trial in the Democratic Republic of Congo, announced September 15. - The broader market is only modestly higher.